Insights From the Experts at Teiko
Learn about the latest advances in immune profiling from Teiko’s team of scientific experts.
Flow vs. Spectral vs. Mass Cytometry: What’s the difference?
What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development.
Five Things to Look For in an Immune Profiling Partner
Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner.
Two Peas in a Pod: The Complementary Capabilities of Single-cell RNA Seq and Mass Cytometry
Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings.
Peripheral Blood Analysis is Key to Developing Effective Cancer Immunotherapies
Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline.